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A bs tr ac t
Background
Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) 
plus docetaxel (TPF) improves outcomes in squamous-cell carcinoma of the head 
and neck. We compared TPF with PF as induction chemotherapy in patients with 
locoregionally advanced, unresectable disease.
Methods
We randomly assigned eligible patients between the ages of 18 and 70 years who 
had stage III or stage IV disease and no distant metastases to receive either TPF 
(docetaxel and cisplatin, day 1; fluorouracil by continuous infusion, days 1 to 5) or 
PF every 3 weeks for four cycles. Patients without progression of disease received 
radiotherapy within 4 to 7 weeks after completing chemotherapy. The primary end 
point was progression-free survival.
Results
A total of 358 patients underwent randomization, with 177 assigned to the TPF group 
and 181 to the PF group. At a median follow-up of 32.5 months, the median pro-
gression-free survival was 11.0 months in the TPF group and 8.2 months in the 
PF group (hazard ratio for disease progression or death in the TPF group, 0.72; 
P = 0.007). Treatment with TPF resulted in a reduction in the risk of death of 27% 
(P = 0.02), with a median overall survival of 18.8 months, as compared with 14.5 
months in the PF group. There were more grade 3 or 4 events of leukopenia and 
neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, 
nausea, vomiting, stomatitis, and hearing loss in the PF group. The rates of death 
from toxic effects were 2.3% in the TPF group and 5.5% in the PF group.
Conclusions
As compared with the standard regimen of cisplatin and fluorouracil, induction 
chemotherapy with the addition of docetaxel significantly improved progression-
free and overall survival in patients with unresectable squamous-cell carcinoma of 
the head and neck. (ClinicalTrials.gov number, NCT00003888.)
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Head and neck cancer, mostly of squamous-cell origin, ranks sixth among the most common cancers, accounting 
for approximately 6% of all cases of cancer. Each 
year, more than 500,000 new cases are diagnosed 
worldwide.1 Approximately 60% of patients pre-
sent with advanced disease (stages III and IV), for 
which the prognosis is poor.2 For many years, 
radiotherapy has been the treatment of choice for 
unresectable disease,3 resulting in 5-year rates of 
survival of less than 20%.4,5
Concurrent chemoradiotherapy has now large-
ly replaced radiotherapy alone in the treatment of 
unresectable squamous-cell carcinoma of the head 
and neck,3,6 but induction chemotherapy has also 
been associated with a survival benefit and could 
be a valuable treatment option.5,7,8 A beneficial ef-
fect of induction chemotherapy has been observed 
only with the Wayne State University regimen of 
cisplatin (at a dose of 100 mg per square meter of 
body-surface area) plus infusional fluorouracil 
(at a dose of 1000 mg per square meter per day for 
5 days), a treatment that has emerged as the most 
active combination9 and that outperformed other 
induction regimens in a large meta-analysis.10 For 
this reason, this regimen can be considered a good 
comparator in randomized trials of new induction 
regimens of chemotherapy. The best number of 
treatment cycles is uncertain, but complete re-
sponse rates increased with each successive cycle 
up to cycle 4 in the study by Paccagnella et al.5
Among agents introduced in the 1990s, the 
taxanes have shown great promise for the treat-
ment of squamous-cell carcinoma of the head and 
neck.11 Phase 2 studies indicate that docetaxel 
plus cisplatin and fluorouracil (TPF) might be 
more efficacious than the classic regimen of cis-
platin plus f luorouracil (PF).12 The Head and 
Neck Cancer Group of the European Organization 
for Research and Treatment of Cancer (EORTC) 
conducted a phase 3 trial, called the EORTC 
24971/TAX 323 study, comparing TPF with PF as 
induction chemotherapy before radiotherapy in pa-
tients with locoregionally advanced, unresectable 
squamous-cell carcinoma of the head and neck.
Me thods
Patients
We conducted an open-label, randomized, strati-
fied phase 3 study at 37 institutions in 15 Euro-
pean countries. The protocol was approved by the 
ethics committee or institutional review board at 
each participating center, and all patients provid-
ed written informed consent.
Eligible patients were between the ages of 18 
and 70 years and had squamous-cell carcinoma 
of the head and neck that had been diagnosed by 
histologic or cytologic analysis. All patients had 
previously untreated and locoregionally advanced 
disease with at least one lesion that was measur-
able either unidimensionally or bidimensionally, 
a tumor–node–metastasis (TNM) stage of III or 
IV without metastases, a World Health Organiza-
tion (WHO) performance status of 1 or less, and 
adequate hematologic, renal, and hepatic func-
tion. Tumors had to be considered unresectable 
by a multidisciplinary team. Patients with tumors 
of the nasopharynx and the nasal and paranasal 
cavities were excluded.
Evaluations were conducted within 7 days be-
fore randomization and included history taking, 
physical examination, hematologic and biochemi-
cal analysis, electrocardiography, magnetic reso-
nance imaging or computed tomography (CT) of 
the head and neck, and chest radiography. Ab-
dominal ultrasonography or CT and bone scan-
ning were performed when indicated.
Study Design
Patients were randomly assigned to study groups 
after verification of eligibility at the EORTC data 
center. Randomization was balanced according to 
the primary tumor site (oral cavity, oropharynx, 
hypopharynx, or larynx) and the center with the 
use of a variance-minimization method.13
Patients were randomly assigned to receive ei-
ther TPF or PF. The TPF regimen consisted of 
docetaxel at a dose of 75 mg per square meter, 
administered as a 1-hour infusion on day 1, fol-
lowed by cisplatin at a dose of 75 mg per square 
meter, administered as a 1-hour infusion on day 1, 
and fluorouracil at a dose of 750 mg per square 
meter per day, administered by continuous infu-
sion on days 1 to 5. The PF regimen consisted of 
cisplatin at a dose of 100 mg per square meter, 
administered as a 1-hour infusion on day 1, fol-
lowed by fluorouracil at a dose of 1000 mg per 
square meter per day, administered by continu-
ous infusion on days 1 to 5. Treatment was ad-
ministered every 3 weeks (defined as one cycle) 
for up to four cycles, unless progressive disease, 
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unacceptable toxic effects, or withdrawal from 
the study occurred earlier. During chemotherapy, 
patients were monitored clinically and with labo-
ratory tests on day 1 of each cycle before treat-
ment. Imaging of tumors was performed at the 
end of cycles 2 and 4.
Patients who did not have progressive disease 
and who had adequate bone marrow function (neu-
trophil count, ≥2.0×103 cells per cubic millimeter; 
platelet count, ≥100×103 cells per cubic millime-
ter; and hemoglobin, ≥10 g per deciliter), com-
plete resolution of mucositis for at least 1 week, 
and healing from any dental procedures under-
went radiotherapy within 4 to 7 weeks after the 
completion of chemotherapy. Radiation was deliv-
ered during a 7-week period with the use of ei-
ther conventional fractionation (total dose, 66 to 
70 Gy) or accelerated or hyperfractionated regi-
mens (total maximum dose of 70 Gy for the accel-
erated regimen and 74 Gy for the hyperfraction-
ated regimen). Each center made a commitment 
before the study began to use one of these meth-
ods. Neck dissection was considered for all pa-
tients before radiotherapy and 3 months after the 
completion of radiotherapy.
The primary end point, progression-free sur-
vival, was defined as the time from randomiza-
tion to progression, relapse, or death, whichever 
occurred first. If progression, relapse, or death 
did not occur before the cutoff date, data were 
censored at the time of the last valid assessment 
before the cutoff date. Secondary end points were 
overall survival, best overall response rate after 
induction chemotherapy and after radiation ther-
apy, duration of response, time to treatment fail-
ure, toxic effects, and health-related quality of 
life, as reported previously.14
The Head and Neck Cancer Group of the 
EORTC conceived and developed the trial, which 
was sponsored by Sanofi-Aventis. The company 
provided docetaxel and was involved in the trial 
design but not in the final analysis. All data were 
collected and analyzed by the academic authors. 
Dr. Vermorken, who vouches for the complete-
ness and accuracy of the data, wrote the article 
with critical review by all the other authors. The 
article was also reviewed by industry representa-
tives, but its final content was determined by the 
academic investigators.
Concomitant Treatment and Dose 
Modifications
All patients received adequate antiemetic medica-
tions during chemotherapy. Dexamethasone (at a 
dose of 8 mg or the equivalent) was given orally 
for a total of six doses, starting the night before 
the administration of chemotherapy, to prevent 
hypersensitivity reactions and to reduce docetaxel-
related skin toxic effects and fluid retention. Pro-
phylactic antibiotics (ciprofloxacin, at a dose of 
500 mg given orally twice daily, or an alternative 
agent) were given to the TPF group only from 
days 5 to 15 of each cycle. Prophylactic granulo-
cyte colony-stimulating factor was permitted only 
if a patient had febrile neutropenia or infection, 
a delay in recovery of the absolute neutrophil count 
at day 28, or grade 4 neutropenia persisting for 
7 days or more.
A cycle could be delayed for up to 2 weeks to 
allow for a reduction in the severity of toxic 
events of grade 3 or more to a severity of grade 1 
or less (with the exception of alopecia, fatigue, 
malaise, and nail changes). Delays beyond 2 weeks 
required discontinuation of chemotherapy. Re-
ductions in the dose of docetaxel were planned 
for grade 4 neutropenia and its complications, 
skin reactions, elevated bilirubin levels, and im-
paired liver function. Modifications in the dose 
of cisplatin were made for peripheral sensory and 
motor neurotoxicity, ototoxicity, or nephrotoxic-
ity; patients with neurotoxicity or ototoxicity of 
grade 3 or more were withdrawn from the study. 
Modifications in the dose of fluorouracil were 
made for mucositis and diarrhea; patients with 
toxic effects of grade 4 were withdrawn from the 
study.
Assessments
Efficacy
Tumor responses were evaluated with the use of 
WHO criteria, which were modified to account 
for the fact that radiotherapy started as soon as 
possible after the end of chemotherapy. Some re-
sponses were not reevaluated 4 weeks after the 
assessment of the initial response.
Safety
Adverse events were graded according to the ex-
panded common toxicity criteria of the Clinical 
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Trials Group of the National Cancer Institute of 
Canada, which were adopted in 1994 for the as-
sessment of morbidity associated with chemother-
apy and radiation. Late adverse events associated 
with radiotherapy were graded according to the 
criteria of the EORTC’s Radiation Therapy Oncol-
ogy Group. Laboratory safety data were assessed 
before the administration of chemotherapy and 
on certain days during and after such treatments, 
as described in the protocol.
Statistical Analysis
The trial had a power of 85% to detect a 50% 
increase in median progression-free survival (15 
months in the TPF group and 10 months in the 
PF group) for a hazard ratio of 0.67. On the basis 
of a 24-month accrual period with a 12-month 
follow-up, an estimated 260 events were required 
from a total accrual of 330 patients (165 per treat-
ment group). On the basis of an anticipated loss 
to follow-up of 5 to 10%, a total of 358 patients 
were enrolled. With this number, the trial had a 
power of 90% to detect an improvement of 15 
percentage points in the 1-year survival rate (85% 
in the TPF group and 70% in the PF group).
A two-sided level of significance of 0.05 was 
applied to all tests. Time-to-event data were 
described with the use of Kaplan–Meier curves. 
Confidence intervals were calculated for median 
progression-free survival and overall survival.15 
Time-to-event intervals were compared between 
groups with the multivariate Cox proportional-
hazards model (primary analysis) and the log-
rank test. In the multivariate analysis, the follow-
ing items were included in the model for each 
analysis: type of treatment, location of primary 
tumor (oral cavity, oropharynx, or hypopharynx), 
tumor stage, regional-node stage, and WHO 
score for performance status. An unadjusted chi-
square test was used to compare response vari-
ables. Fisher’s exact test was used to compare 
other binary and categorical variables. Continu-
ous measurements and scores were compared 
with the Wilcoxon test.
All efficacy analyses were conducted in the 
intention-to-treat population. Patients could be 
evaluated for a response (according to modified 
WHO criteria) if all baseline lesions were assessed 
at least once after the second chemotherapy cycle 
by means of the same method used at baseline. 
The safety population included only patients who 
received their randomly assigned treatment.
All patients were followed until death. Patients 
with progressive disease at any time were referred 
to the radiation oncologist according to the insti-
tution’s policy and were followed for survival only.
R esult s
Patients
Between April 1999 and March 2002, a total of 358 
patients were randomly assigned to study groups, 
with 181 assigned to receive PF and 177 assigned 
to receive TPF. The two treatment groups were 
balanced according to baseline demographic and 
clinical characteristics (Table 1).
Exposure to Study Treatment
The numbers of patients who were enrolled and 
who completed the study are shown in Figure 1. 
Most patients (75.7% in the TPF group and 65.7% 
in the PF group) completed the chemotherapy as 
defined by the protocol. Treatment groups were 
similar with respect to the number of chemo-
therapy cycles and duration of treatment (Table 1 
of the Supplementary Appendix, available with the 
full text of this article at www.nejm.org). Protocol-
defined chemotherapy doses were administered in 
95% of cycles in the TPF group and in 91% of cy-
cles in the PF group. Before the scheduled com-
pletion of the study, 38 patients in the TPF group 
and 60 in the PF group discontinued chemother-
apy (P = 0.02). The most frequent reasons for dis-
continuation were progressive disease (7.9% in the 
TPF group and 7.2% in the PF group), adverse 
events (6.2% in the TPF group and 11.6% in the 
PF group), and death (3.4% in the TPF group and 
6.6% in the PF group).
Dose reductions were made mostly because of 
nonhematologic toxic effects. Dose delays were 
more common in the PF group (Table 1 of the 
Supplementary Appendix). The most frequent rea-
sons for dose delays were hematologic toxic ef-
fects in the PF group (64.8%, vs. 10.9% in the TPF 
group; P<0.001) and other reasons (mainly ad-
ministrative) in the TPF group (84.8%, vs. 29.5% 
in the PF group; P<0.001). The majority of pa-
tients received conventional radiotherapy, but four 
investigators delivered more than one type of ra-
diotherapy. Only eight patients in the TPF group 
The New England Journal of Medicine 
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Table 1. Baseline Characteristics of the Patients (Intention-to-Treat Population).*
Characteristic
PF 
(N = 181)
TPF 
(N = 177)
Total 
(N = 358) P Value
Male sex — no. (%) 162 (89.5) 159 (89.8) 321 (89.7) 0.87
Age — yr 0.77
Median 53 53 53
Range 30–71 31–70 30–71
Age — no. (%)
<35 yr 4 (2.2) 2 (1.1) 6 (1.7)
35–49 yr 58 (32.0) 53 (29.9) 111 (31.0)
50–64 yr 101 (55.8) 104 (58.8) 205 (57.3)
65–75 yr 18 (9.9) 18 (10.2) 36 (10.1)
WHO performance status — no. (%)† 0.96
0 91 (50.3) 90 (50.8) 181 (50.6)
1 90 (49.7) 86 (48.6) 176 (49.2)
2 0 1 (0.6) 1 (0.3)
Cancer site — no. (%)
Hypopharynx 52 (28.7) 53 (29.9) 105 (29.3) 0.99
Larynx 13 (7.2) 12 (6.8) 25 (7.0)
Oral cavity 32 (17.7) 31 (17.5) 63 (17.6)
Oropharynx 84 (46.4) 81 (45.8) 165 (46.1)
Tumor status — no. (%) 0.50
T1 1 (0.6) 3 (1.7) 4 (1.1)
T2 15 (8.3) 10 (5.6) 25 (7.0)
T3 36 (19.9) 41 (23.2) 77 (21.5)
T4 129 (71.3) 123 (69.5) 252 (70.4)
Node status — no. (%) 0.09
N0 26 (14.4) 16 (9.0) 42 (11.7)
N1 29 (16.0) 27 (15.3) 56 (15.6)
N2 103 (56.9) 102 (57.6) 205 (57.3)
N3 20 (11.0) 32 (18.1) 52 (14.5)
Unknown 3 (1.7) 0 3 (0.8)
Disease sites in head and neck — no. (%) 0.77
1 25 (13.8) 19 (10.7) 44 (12.3)
2 140 (77.3) 150 (84.7) 290 (81.0)
≥3 13 (7.2) 7 (4.0) 20 (5.6)
No tumor assessment at baseline — no. (%) 3 (1.7) 1 (0.6) 4 (1.1)
* PF denotes cisplatin–fluorouracil, TPF docetaxel–cisplatin–fluorouracil, and WHO World Health Organization. Percent-
ages may not total 100 because of rounding.
† A performance status of 0 denotes asymptomatic, 1 symptomatic and fully ambulatory, and 2 symptomatic and in bed 
less than 50% of the day.
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(5%) and five in the PF group (3%) discontinued 
the planned radiotherapy. Radiotherapy that was 
not defined in the protocol was administered to 
27 of 44 patients in the TPF group (61%) and 32 
of 59 patients in the PF group (54%) who had a 
recurrence while receiving induction chemother-
apy. In total, 17 patients in the TPF group (10%) 
and 27 patients in the PF group (15%) did not 
receive radiotherapy (P = 0.15).
Efficacy
After a median follow-up of 32.5 months, a total 
of 273 patients had disease progression or had 
died (126 in the TPF group and 147 in the PF 
group). Treatment with TPF resulted in a relative 
reduction of 28% in the risk of disease progres-
sion or death, as compared with PF (P = 0.007) 
(Fig. 2A) and significantly improved median pro-
gression-free survival, median overall survival, 
and time to treatment failure (Table 2).
The overall response rate in the TPF group was 
significantly higher than that in the PF group, 
both in the induction-chemotherapy phase and 
after locoregional therapy. Although the complete-
response rate was similar in the two groups in 
the induction-chemotherapy phase, it was signifi-
cantly higher in the TPF group than in the PF 
group after locoregional therapy (33.3% vs. 19.9%, 
P = 0.004) (Table 2).
In a survival update performed on July 18, 
2005, at a median follow-up of 51.1 months, 268 
patients had died (122 in the TPF group and 146 
in the PF group) (Fig. 2B).
Pattern of First Relapse
The total number of relapses was 101 in the TPF 
group (57.1%) and 117 in the PF group (64.6%). 
Most first relapses occurred at the locoregional 
disease site (85.1% in the TPF group and 81.2% 
in the PF group). Distant relapses were observed 
in 12.9% of patients in the TPF group and in 10.3% 
in the PF group. Of the 25 patients with distant 
metastases, 5 also had locoregional relapse.
Surgery
Elective neck dissections were performed before 
radiotherapy in seven patients in the TPF group 
and four patients in the PF group and after radio-
therapy in nine patients in the TPF group and 
three patients in the PF group. Thus, a total of 16 
patients in the TPF group and 7 patients in the PF 
group underwent neck dissection (P = 0.05). After 
disease progression, 42 patients — 27 in the TPF 
group and 15 in the PF group — underwent sur-
gery (P = 0.05). Thus, a total of 60 patients under-
went surgery of any type during the study: 40 in 
the TPF group and 20 in the PF group (P = 0.003).
A separate survey was performed among the 
42 patients with progressive disease to determine 
whether resection had a curative or palliative in-
tent. For 28 patients (20 in the TPF group and 8 in 
the PF group), the surgical intent was palliative, 
and for 10 patients (4 in the TPF group and 6 in 
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Figure 1. Enrollment and Outcomes. 
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on July 13, 2012. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
cisplatin–fluorour acil–docetaxel in Head and Neck Cancer
n engl j med 357;17 www.nejm.org october 25, 2007 1701
the PF group), it was curative. For four patients, 
the intent of surgery was unknown. No signifi-
cant difference was observed in the distribution 
between the two groups (P = 0.22).
Adverse Events
During chemotherapy, the most frequently ob-
served severe nonhematologic adverse events were 
alopecia, stomatitis, infections, nausea, vomiting, 
anorexia, diarrhea, and hearing loss (Table 3). 
Apart from alopecia and infections, these adverse 
events were more frequent in the PF group than 
in the TPF group. Grade 3 or 4 neutropenia and 
leukopenia were more common in the TPF group, 
and severe thrombocytopenia and anemia were 
more common in the PF group. Febrile neutrope-
nia occurred in 5.2% of patients in the TPF group 
and 2.8% in the PF group.
During radiotherapy, the most frequent treat-
ment-related severe adverse events were stomati-
tis (23.7% in the TPF group and 20.7% in the PF 
group) and a combination of esophagitis, dyspha-
gia, and odynophagia (13.9% in the TPF group 
and 15.6% in the PF group).
Deaths associated with toxic effects occurred 
in 4 patients in the TPF group (2.3%) and in 10 
patients in the PF group (5.5%) (P = 0.17).
Discussion
Our study showed that induction chemotherapy 
with TPF resulted in significant and clinical mean-
ingful improvements in outcomes, as compared 
with PF, in locoregionally advanced, unresectable 
squamous-cell carcinoma of the head and neck. 
Patients who were treated with TPF had a reduc-
tion of 28% in the risk of disease progression or 
death, as compared with those who received PF. 
They also had an extension of 2.8 months in medi-
an progression-free survival. This result was asso-
ciated with significant improvements in overall sur-
vival, overall response rates, and time to treatment 
failure. Patients in the TPF group had a reduction 
of 27% in the risk of death, an improvement in 
median overall survival of 4.3 months, and an 
absolute increase in 3-year survival of 10.9%.
Selection of the TPF regimen that was used in 
this phase 3 study was based on results of an 
earlier phase 1 and 2 study of four cycles of TPF 
used as induction chemotherapy in a similar pa-
tient population.16 The median survival among 
the 48 patients treated in that study was 18.5 
months; the rate of survival at 12, 24, and 36 
months was 69%, 41%, and 31%, respectively. 
These data are remarkably similar to those in 
the TPF group in our phase 3 trial. However, our 
results in the TPF group are inferior to those of 
other phase 2 studies, which showed 2-year sur-
vival rates of 60 to 83% and overall response rates 
of 88 to 100%; this difference may be due to the 
heterogeneity of the patient populations.17
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Figure 2. Effects of TPF and PF Therapy on Progression-free Survival (Panel A) 
and Overall Survival (Panel B).
TPF denotes docetaxel–cisplatin–fluorouracil, and PF cisplatin–fluorouracil.
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In our trial, survival was shorter than that 
reported in two other phase 3 trials of taxane-
containing induction chemotherapy regimens.18,19 
The U.S. trial, a study by Posner et al.18 of con-
current chemotherapy and radiotherapy after 
induction chemotherapy (TAX 324), used a mod-
ified TPF regimen. The Spanish trial by Hitt et 
al.19 used PF plus paclitaxel (PPF). However, 
these trials included both patients with resect-
able disease and those with unresectable dis-
ease. In the study by Posner et al., reported in 
this issue of the Journal, the median survival was 
71 months in the TPF group and 30 months in 
the PF group. The Spanish study showed a sig-
nificant survival benefit only in patients with 
unresectable disease (median survival, 36 months 
in the PPF group and 26 months in the PF 
group). In contrast, in the study by Paccagnella 
et al.,5,7 the survival curve for patients with un-
resectable disease who were treated with PF fol-
lowed by radiotherapy was identical to that for 
the PF group in our study.
As expected, TPF induced more leukopenia 
and neutropenia than PF but did not lead to 
more frequent infectious complications when 
patients received prophylactic antibiotics. Over-
all, TPF led to fewer treatment delays and was 
associated with fewer deaths from toxic effects 
(2.3% in the TPF group and 5.5% in the PF 
group). PF was associated with more grade 3 or 
Table 2. Response to Treatment and Survival.*
Variable
PF
(N = 181)
TPF
(N = 177) Hazard Ratio (95% CI) P Value
Progression-free survival
Median duration — mo 8.2 11.0 0.72 (0.57–0.91) 0.007†
Rate — %
At 1 yr 31 48
At 2 yr 20 25
At 3 yr 14 17
Overall survival
Median duration — mo 14.5 18.8 0.73 (0.56–0.94) 0.02†
Rate — %
At 1 yr 55 72
At 2 yr 32 43
At 3 yr 26 37
Response to chemotherapy 
Overall — % 54 68 0.006‡
Complete — no. (%) 12 (6.6) 15 (8.5)
Partial — no. (%) 85 (47.0) 105 (59.3)
Response to chemotherapy and radiotherapy
Overall — % 59 72 0.006‡
Complete — no. (%) 36 (19.9) 59 (33.3) 0.004‡
Partial — no. (%) 70 (38.7) 69 (39.0)
Duration of response — mo 11.6 15.4 0.74 (0.53–1.03) 0.08§
Time to treatment failure — mo 7.8 10.5 0.70 (0.55–0.89) 0.003†
* PF denotes cisplatin–fluorouracil, and TPF docetaxel–cisplatin–fluorouracil.
† The P value was calculated with the use of an adjusted Cox proportional-hazards model.
‡ The P value was calculated with the use of an unadjusted chi-square test.
§  The P value was calculated with the use of an unadjusted log-rank test.
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4 events of thrombocytopenia, nausea, vomiting, 
stomatitis, and hearing loss than was TPF. The 
improved tolerability of the triple regimen was 
also observed in the Spanish trial of PPF but was 
less evident in the TAX 324 study. The reduced 
doses of fluorouracil and cisplatin administered 
in our study probably reduced the toxicity.
Rates of locoregional control and survival 
improve more after accelerated or hyperfraction-
ated radiotherapy than after conventionally frac-
tionated radiotherapy.20,21 At the time our trial 
started, these radiotherapy standards had not 
been universally accepted within the EORTC’s 
Head and Neck Cancer Group, so most of our 
patients received standard fractionation. How-
ever, even with these improvements, the out-
comes for patients with unresectable disease 
remain dismal. Our study and the study by Pos-
ner et al.18 raise two questions. First, is induc-
tion TPF followed by radiotherapy alone equiva-
lent or superior to chemoradiotherapy? Second, 
do induction chemotherapy and chemoradio-
therapy have complementary effects on overall 
control of disease? At least five ongoing ran-
domized trials evaluating induction chemother-
apy followed by chemoradiotherapy may provide 
the answer.22-24
In conclusion, our study showed that the ad-
dition of docetaxel to PF induction chemothera-
py in patients with unresectable squamous-cell 
carcinoma of the head and neck improved sur-
vival and was better tolerated than the classic PF 
regimen.
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Table 3. Grade 3 or 4 Hematologic and Nonhematologic Adverse Events 
 during Chemotherapy (Safety Population).*
Event PF (N = 179) TPF (N = 173)
no. of patients (%)
Hematologic†
Neutropenia 94 (52.5) 133 (76.9)
Anemia 23 (12.8) 16 (9.2)
Thrombocytopenia 32 (17.9) 9 (5.2)
Leukopenia 41 (22.9) 72 (41.6)
Nonhematologic‡
Alopecia 0 20 (11.6)
Nausea 12 (6.7) 1 (0.6)
Stomatitis 20 (11.2) 8 (4.6)
Lethargy 3 (1.7) 5 (2.9)
Diarrhea 6 (3.4) 5 (2.9)
Vomiting 8 (4.5) 1 (0.6)
Neurotoxicity 1 (0.6) 1 (0.6)
Anorexia 6 (3.4) 1 (0.6)
Infection 11 (6.1) 12 (6.9)
Febrile neutropenia 5 (2.8) 9 (5.2)
Weight loss 1 (0.6) 0
Local toxic effect 1 (0.6) 1 (0.6)
Constipation 1 (0.6) 0
Hearing loss 5 (2.8) 0
Esophagitis, dysphagia, or  
odynophagia 
0 1 (0.6)
Gastrointestinal pain 1 (0.6) 0 
* PF denotes cisplatin–fluorouracil, and TPF docetaxel–cisplatin–fluorouracil.
† Hematologic toxic effects are listed regardless of whether there was a relation-
ship with a study drug.
‡ Nonhematologic toxic effects were related to treatment.
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